SOAT1 and Leigh syndrome: The potential repurposing of existing drugs targeting these pathways, such as nintedanib (a tyrosine kinase inhibitor), tocilizumab (targeting the IL-6 receptor), and JAK/STAT inhibitors, could be explored for LS treatment [48,49,50].